BACKGROUND Brain gliomas are malignant tumors with high postoperative recurrence rates.Early prediction of prognosis using specific indicators is of great significance.AIM To assess changes in ubiquitin carboxy-termin...BACKGROUND Brain gliomas are malignant tumors with high postoperative recurrence rates.Early prediction of prognosis using specific indicators is of great significance.AIM To assess changes in ubiquitin carboxy-terminal hydrolase L1(UCH-L1)and glial fibrillary acidic protein(GFAP)levels in patients with glioma pre-and postoperatively.METHODS Between June 2018 and June 2021,91 patients with gliomas who underwent surgery at our hospital were enrolled in the glioma group.Sixty healthy volunteers were included in the control group.Serum UCH-L1 and GFAP levels were measured in peripheral blood collected from patients with glioma before and 3 d after surgery.UCH-L1 and GFAP levels in patients with glioma with different clinicopathological characteristics were compared before and after surgery.The patients were followed-up until February 2022.Postoperative glioma recurrence was recorded to determine the serum UCH-L1 and GFAP levels,which could assist in predicting postoperative glioma recurrence.RESULTS UCH-L1 and GFAP levels in patients with glioma decreased significantly 3 d after surgery compared to those before therapy(P<0.05).However,UCH-L1 and GFAP levels in the glioma group were significantly higher than those in the control group before and after surgery(P<0.05).There were no statistically significant differences in preoperative serum UCH-L1 and GFAP levels among patients with glioma according to sex,age,pathological type,tumor location,or number of lesions(P>0.05).Serum UCH-L1 and GFAP levels were significantly lower in the patients with WHO grade I-II tumors than in those with gradeⅢ-IV tumors(P<0.05).Serum UCH-L1 and GFAP levels were lower in the patients with tumor diameter≤5 cm than in those with diameter>5 cm,in which the differences were statistically significant(P<0.05).Glioma recurred in 22 patients.The preoperative and 3-d postoperative serum UCH-L1 and GFAP levels were significantly higher in the recurrence group than these in the non-recurrence group(P<0.05).Receiver operating characteristic curves were plotted.The areas under the curves of preoperative serum UCH-L1 and GFAP levels for predicting postoperative glioma recurrence were 0.785 and 0.775,respectively.However,the efficacy of serum UCH-L1 and GFAP levels 3 d after surgery in predicting postoperative glioma recurrence was slightly lower compared with their preoperative levels.CONCLUSION UCH-L1 and GFAP efficiently reflected the development and recurrence of gliomas and could be used as potential indicators for the recurrence and prognosis of glioma.展开更多
以程序性死亡配体1/程序性死亡受体1(programmed cell death ligand 1/programmed cell death protein 1,PD-L1/PD-1)免疫检查点阻断治疗为代表的肿瘤免疫疗法在临床上取得了令人鼓舞的治疗效果。小分子肿瘤免疫治疗药物与免疫检查点抗...以程序性死亡配体1/程序性死亡受体1(programmed cell death ligand 1/programmed cell death protein 1,PD-L1/PD-1)免疫检查点阻断治疗为代表的肿瘤免疫疗法在临床上取得了令人鼓舞的治疗效果。小分子肿瘤免疫治疗药物与免疫检查点抗体药物的联用,为肿瘤治疗提供了新策略。因此,研发能阻断PD-L1/PD-1免疫检查点相互作用的小分子药物是下一代肿瘤免疫疗法的新方向。本研究对丹酚酸B(salvianolic acid B,SAB)下调肿瘤细胞中PD-L1表达发挥抗肿瘤作用及机制进行了研究。利用Western blot、流式细胞术、PD-1/PD-L1相互作用分析SAB对结肠癌细胞RKO和前列腺癌细胞PC3细胞内和膜表面PD-L1蛋白表达水平的影响;荧光定量PCR检测SAB对PD-L1 mRNA的影响;细胞阻抗法和结晶紫法检测SAB对人类外周血单核细胞(peripheral blood mononuclear cell,PBMC)杀伤肿瘤细胞的效果;表面等离子共振技术分析SAB与泛素羧基末端水解酶2(ubiquitin carboxyl-terminal hydrolase 2,USP2)的直接相互作用;MC38荷瘤小鼠(所有动物实验均遵循中国医学科学院医药生物技术研究所伦理委员会的规定)检测SAB的体内抑瘤效果。结果表明,SAB能分别以浓度依赖性和时间依赖性方式下调RKO、PC3细胞中以及细胞膜表面PD-L1的水平,这与SAB抑制肿瘤细胞中去泛素化酶USP2的活性有关。机制研究发现,SAB可与USP2发生直接相互作用并抑制其去泛素化酶活性,从而促进PD-L1发生泛素-蛋白酶体途径降解。此外,SAB可促进共培养的PBMC对RKO细胞的杀伤作用。小鼠荷瘤实验证实,SAB可显著抑制C57BL/6小鼠中MC38移植瘤的生长。20 mg·kg^(-1) SAB处理荷瘤小鼠后,可使瘤体积减少63.2%。以上结果说明,SAB通过直接结合USP2并抑制其活性,促进PD-L1发生泛素-蛋白酶体途径降解,从而发挥抗肿瘤作用。本研究为将SAB研发成靶向USP2-PD-L1轴的小分子肿瘤免疫治疗药物奠定了基础。展开更多
基金Supported by Hebei Medical Science Research Project,No.20220648。
文摘BACKGROUND Brain gliomas are malignant tumors with high postoperative recurrence rates.Early prediction of prognosis using specific indicators is of great significance.AIM To assess changes in ubiquitin carboxy-terminal hydrolase L1(UCH-L1)and glial fibrillary acidic protein(GFAP)levels in patients with glioma pre-and postoperatively.METHODS Between June 2018 and June 2021,91 patients with gliomas who underwent surgery at our hospital were enrolled in the glioma group.Sixty healthy volunteers were included in the control group.Serum UCH-L1 and GFAP levels were measured in peripheral blood collected from patients with glioma before and 3 d after surgery.UCH-L1 and GFAP levels in patients with glioma with different clinicopathological characteristics were compared before and after surgery.The patients were followed-up until February 2022.Postoperative glioma recurrence was recorded to determine the serum UCH-L1 and GFAP levels,which could assist in predicting postoperative glioma recurrence.RESULTS UCH-L1 and GFAP levels in patients with glioma decreased significantly 3 d after surgery compared to those before therapy(P<0.05).However,UCH-L1 and GFAP levels in the glioma group were significantly higher than those in the control group before and after surgery(P<0.05).There were no statistically significant differences in preoperative serum UCH-L1 and GFAP levels among patients with glioma according to sex,age,pathological type,tumor location,or number of lesions(P>0.05).Serum UCH-L1 and GFAP levels were significantly lower in the patients with WHO grade I-II tumors than in those with gradeⅢ-IV tumors(P<0.05).Serum UCH-L1 and GFAP levels were lower in the patients with tumor diameter≤5 cm than in those with diameter>5 cm,in which the differences were statistically significant(P<0.05).Glioma recurred in 22 patients.The preoperative and 3-d postoperative serum UCH-L1 and GFAP levels were significantly higher in the recurrence group than these in the non-recurrence group(P<0.05).Receiver operating characteristic curves were plotted.The areas under the curves of preoperative serum UCH-L1 and GFAP levels for predicting postoperative glioma recurrence were 0.785 and 0.775,respectively.However,the efficacy of serum UCH-L1 and GFAP levels 3 d after surgery in predicting postoperative glioma recurrence was slightly lower compared with their preoperative levels.CONCLUSION UCH-L1 and GFAP efficiently reflected the development and recurrence of gliomas and could be used as potential indicators for the recurrence and prognosis of glioma.
